Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines.

Immunization 52

Immunization Vaccines 52

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Both drugs come with a high price tag. To an extent, the challenge here lies in the nature of antibodies, says Contreras.

FDA 104

FDA 104

pharmaphorum

JANUARY 18, 2022

The use of monovalent degraders, which enable the targeted degradation of disease-relevant proteins, offers a new avenue to reach tissue that cannot be targeted with conventional therapeutic agents. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.

Immunization 52

Immunization 52

Pharmaceutical Technology

MAY 15, 2023

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

Immunization 52

Immunization Hospitals Vaccines 52

The Checkup by Singlecare

JANUARY 15, 2023

Besides cholinesterase enzyme inhibitors, Namenda, an NMDA antagonist, is also available as a therapeutic for Alzheimer’s disease. Aduhelm is a monoclonal antibody that targets amyloid beta, the protein which piles up in the brain and seems to be at the root of the disease. Compare donepezil alternatives. Savings options.

Dosage 52

Dosage FDA Insurance 52

Roots Analysis

SEPTEMBER 13, 2023

Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Labelling 40

Labelling 40

European Pharmaceutical Review

NOVEMBER 10, 2022

Complex medicines offer diverse therapeutic modalities, including RNA therapeutics and antibody-drug conjugates (ADCs). BT-474 cell line was gene-edited to incorporate a green fluorescent protein (GFP) tag into late endosomes/lysosomes (green). Physical characterisation.

Labelling 96

Labelling Compounding 96

pharmaphorum

DECEMBER 2, 2020

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The New York-based firm has requested approval for the combination of its anti-CD20 antibody ublituximab and umralisib, an oral drug that inhibits PI3K-delta and CK-1 epsilon.

FDA 52

FDA Chemotherapy 52

European Pharmaceutical Review

DECEMBER 27, 2023

Additionally, it was not recommended to use low-dose steroids or allow early administration of tocilizumab, a monoclonal antibody targeting the interleukin-6 (IL-6), in order to reduce and prevent severe CRS. This is in addition to its considerable price tag.

Adverse Reactions 83

Adverse Reactions Immunization Medical Schools Chemotherapy 83